reported that in the patient-derived xenograft models with a PI3K mutation or amplification, the combination groups (pictilisib with cisplatin and/or gemcitabine) achieved significant delay of tumor growth and increased survival compared with any single drug (pictilisib/cisplatin/gemcitabine) (75). This evidence concerns the gene PIK3CA and neoplasm.